Gilead Sciences stock kpis
Want to see GILD full AI Analyst Report?
Revenue by Type
Gilead Sciences reported revenue by type of $8.30B in Q3 2026, up 6.4% from Q2 2026 and up 6.8% year over year. This is the highest value since 2019.
Analyzes income from different sources, highlighting which areas are driving growth and which might be underperforming, crucial for assessing the company's financial health and strategic focus.
Product sales are the clear growth engine — steady, upward momentum driven by HIV/PrEP strength and oncology launches that prompted management to raise product/base guidance. ‘Other’ is highly erratic and driven by one‑off items (nonrecurring other revenue, licensing/transactional effects), producing outsized spikes that can misleadingly swing reported results. For investors, prioritize the underlying product trajectory and HIV/PrEP/Trodelvy momentum rather than headline EPS volatility from acquisition accounting and tax distortions; watch cell‑therapy softness and lower COVID sales as potential near‑term offsets to product gains.
GILD Revenue by Type
| Period | Other | Product | Total |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | $11.00M | $8.29B | $8.30B |
| Q2 2026Jun 30, 2026 | $176.00M | $7.63B | $7.80B |
| Q1 2026Mar 31, 2026 | $14.00M | $6.95B | $6.96B |
| Q4 2025Dec 31, 2025 | $22.00M | $7.90B | $7.92B |
| Q3 2025Sep 30, 2025 | $424.00M | $7.34B | $7.77B |
| Q2 2025Jun 30, 2025 | $27.00M | $7.05B | $7.08B |
| Q1 2025Mar 31, 2025 | $54.00M | $6.61B | $6.67B |
| Q4 2024Dec 31, 2024 | $33.00M | $7.54B | $7.57B |
| Q3 2024Sep 30, 2024 | $30.00M | $7.51B | $7.54B |
| Q2 2024Jun 30, 2024 | $41.00M | $6.91B | $6.95B |
| Q1 2024Mar 31, 2024 | $39.00M | $6.65B | $6.69B |
| Q4 2023Dec 31, 2023 | $45.00M | $7.07B | $7.12B |
| Q3 2023Sep 30, 2023 | $56.00M | $6.99B | $7.05B |
| Q2 2023Jun 30, 2023 | $35.00M | $6.56B | $6.60B |
| Q1 2023Mar 31, 2023 | $46.00M | $6.31B | $6.35B |
| Q4 2022Dec 31, 2022 | $56.00M | $7.33B | $7.39B |
| Q3 2022Sep 30, 2022 | $64.00M | $6.98B | $7.04B |
| Q2 2022Jun 30, 2022 | $122.00M | $6.14B | $6.26B |
| Q1 2022Mar 31, 2022 | $56.00M | $6.53B | $6.59B |
| Q4 2021Dec 31, 2021 | $84.00M | $7.16B | $7.24B |
| Q3 2021Sep 30, 2021 | $65.00M | $7.36B | $7.42B |
| Q2 2021Jun 30, 2021 | $65.00M | $6.15B | $6.22B |
| Q1 2021Mar 31, 2021 | $83.00M | $6.34B | $6.42B |
| Q4 2020Dec 31, 2020 | $93.00M | $7.33B | $7.42B |
| Q3 2020Sep 30, 2020 | $84.00M | $6.49B | $6.58B |
| Q2 2020Jun 30, 2020 | $76.00M | $5.07B | $5.14B |
| Q1 2020Mar 31, 2020 | $81.00M | $5.47B | $5.55B |
| Q4 2019Dec 31, 2019 | $83.00M | $5.80B | $5.88B |

